Education
About Us
Working with TipRanks
Follow Us
10X Genomics (GB:0A88)
:0A88
0A88 Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.95 - $24.60
Previous CloseN/A
Volume1.96K
Average Volume (3M)3.35K
Market Cap
$1.58B
Enterprise Value$4.02B
Total Cash (Recent Filing)$426.90M
Total Debt (Recent Filing)$80.07M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Aug 07, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding111,092,770
10 Day Avg. Volume2,670
30 Day Avg. Volume3,352
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-25.10
Enterprise Value/Market Cap2.55
Enterprise Value/Revenue1.61
Enterprise Value/Gross Profit9.37
Enterprise Value/Ebitda-6.94
Forecast
1Y Price Target
$13.00Price Target Upside2.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
10x Genomics News
PremiumCompany Announcements
10x Genomics Elects Directors at Annual Meeting
Bulls Say, Bears Say
Bulls Say
Consumables RevenueConsumables revenue was ahead of expectations, driven by broader Xenium utilization.
Legal SettlementThe resolution of legal disputes is particularly welcome given the tough macro and industry environments, aiding in 10x's operational stability.
Service RevenueService revenue increased by 47% year-over-year, outperforming market expectations.
Bears Say
Instrument PlacementsInstrument placements decreased significantly due to funding concerns in the US academic and government markets.
Revenue Guidance Withdrawal10x Genomics withdrew its 2025 revenue guidance due to macro uncertainty, which has led to unpredictable customer purchasing behavior and reduced visibility.
US Academic Market ChallengesTXG faces significant pressure from the US academic end-market, which accounts for 40-50% of TXG revenue.
Options Prices
Currently, No data available
---
Ownership Overview
2.54% Insiders
23.20%
Mutual Funds
36.54% Other Institutional Investors
12.78% Public Companies and Individual Investors
0A88 FAQ
What was 10X Genomics’s price range in the past 12 months?
10X Genomics lowest share price was $6.95 and its highest was $24.60 in the past 12 months.
What is 10X Genomics’s market cap?
10X Genomics’s market cap is $1.58B.
When is 10X Genomics’s upcoming earnings report date?
10X Genomics’s upcoming earnings report date is Aug 07, 2025 which is in 26 days.
How were 10X Genomics’s earnings last quarter?
10X Genomics released its earnings results on May 08, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.467 by $0.187.
Is 10X Genomics overvalued?
According to Wall Street analysts 10X Genomics’s price is currently Undervalued.
Does 10X Genomics pay dividends?
10X Genomics does not currently pay dividends.
What is 10X Genomics’s EPS estimate?
10X Genomics’s EPS estimate is -0.37.
How many shares outstanding does 10X Genomics have?
10X Genomics has 111,092,770 shares outstanding.
What happened to 10X Genomics’s price movement after its last earnings report?
10X Genomics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.467. Following the earnings report the stock price went up 5.784%.
Which hedge fund is a major shareholder of 10X Genomics?
Currently, no hedge funds are holding shares in GB:0A88
10x Genomics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (2.36% Upside)
$13.00 (2.36% Upside)
Blogger Sentiment
Neutral
GB:0A88 Sentiment 50%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $173.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.66%
12-Months-Change
Fundamentals
Return on Equity
-22.03%
Trailing 12-Months
Asset Growth
-2.11%
Trailing 12-Months
Company Description
10X Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
0A88 Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While there were significant achievements in consumables growth, particularly in APAC, and promising product developments, these were overshadowed by declines in instrument revenue and substantial uncertainties in the U.S. research funding environment. The company's decision to withdraw full-year guidance reflects this uncertainty.Read More>0A88 Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
0A88 Stock 12 Month Forecast
Average Price Target
$13.00
▲(2.36%Upside)